Journal Mobile Options
Table of Contents
Vol. 16, No. 2, 2001
Issue release date: March–April 2001
Fetal Diagn Ther 2001;16:105–110
(DOI:10.1159/000053891)

Outcome of Fetal Cystic Hygroma and Experience of Intrauterine Treatment

Ogita K. · Suita S. · Taguchi T. · Yamanouchi T. · Masumoto K. · Tsukimori K. · Nakano H.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Objective: To review our cases of fetal cystic hygroma and to examine the prognostic factors with the goal of establishing criteria for the intrauterine treatment for cystic hygroma. Patients and Methods: Thirty-one cases of fetal cystic hygroma were managed by us from January 1988 to December 1997, and 21 cases were available for analysis. Three prognostic factors, namely chromosomal abnormality, structural anomaly and hydrops fetalis, were evaluated. We treated 2 cases of cystic hygroma associated with hydrops fetalis in utero using OK-432 injection under ultrasound guidance. Results: The fetuses without any of the prognostic factors listed above showed a good prognosis throughout the fetal and neonatal periods. However, in this group, 2 infants with large tumors died of hemorrhage from the tumor at 6 months and 3 years of age, respectively. Cases with hydrops fetalis without chromosomal abnormalities or structural anomalies (5 cases) resulted in either intrauterine fetal death (IUFD, 2 cases) or early perinatal neonatal death (early PND, 3 cases). The cause of early PND was circulatory failure. Most of the hydrops cases with either a chromosomal abnormality or structural anomaly resulted in IUFD before 22 weeks of gestation. The size of the cyst decreased in 1 of 2 cases treated in utero. Conclusions: The fetal cases of cystic hygroma showing hydrops fetalis without chromosomal abnormalities or structural anomalies are considered to be possible candidates for intrauterine therapy. Those with very large cystic hygroma without any of the three prognostic factors are also thought to be candidates for fetal treatment. Based on our clinical experience, sclerotherapy using OK-432 is considered to be a treatment option in selected cases with fetal cystic hygroma.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Chervenak FA, Glenn I, Blakemore KJ, Breg WR, Hobbins JC, Berkowitz RL, Tortora M, Mayden K, Mahoney MJ: Fetal cystic hygroma: Cause and natural history. N Engl J Med 1983;309:822–825.
  2. Anderson NG, Kennedy JC: Prognosis in fetal cystic hygroma. Aust NZ J Obstet Gynaecol 1992;32:1:36–39.
  3. Pijpers L, Reuss A, Stewart PA, Wladimiroff JW, Sachs ES: Fetal cystic hygroma: Prenatal diagnosis and management. Obstet Gynecol 1988;72:223–224.
  4. Nadel A, Bromley B, Benacerraf BR: Nuchal thickening or cystic hygromas in first- and early second-trimester fetuses: Prognosis and outcome. Obstet Gynecol 1993;82:43–48.
  5. Watari H, Yamada H, Fujino T, Okuyama K, Sagawa T, Makinoda S, Fujimoto S: A case of intrauterine medical treatment for cystic hygroma. Eur J Obstet Gynecol Reprod Biol 1996;70:201–203.
  6. Takeuchi T, Toko A, Hagiya N, Tenjin N, Kamoi S, Shin S, Araki T: A trial therapy case of fetal cystic hygroma in 2nd trimester (in Japanese). Tokyo J Obstet Gynecol 1993;42:338–341.
  7. Ogita S, Tsuto T, Tokiwa K, Takahashi T: Intracystic injection of OK-432: A new sclerosing therapy for cystic hygroma in children. Br J Surg 1987;74:690–691.
  8. Ogita S, Tsuto T, Deguchi E, Tokiwa K, Nagashima M, Iwai N: OK-432 therapy for unresectable lymphangiomas in children. J Pediatr Surg 1991;26:263–270.
  9. Negishi H, Yamada H, Okuyama K, Sagawa T, Makinoda S, Fujimoto S: Outcome of non-immune hydrops fetalis and a fetus with hydrothorax and/or ascites: with some trials of intrauterine treatment. J Perinat Med 1997;25:71–77.
  10. Maeda H, Koyanagi T, Nakano H: Intrauterine treatment on non-immune hydrops fetalis. Early Hum Dev 1994;29:241–249.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50